Page 87 - Drug Class Review
P. 87
Drug Effectiveness Review Project
Alzheimer Drugs Authors: Brodaty et al. 49 Year: 2005 Country: Multinational (US, Australia, Canada, South Africa, New Zealand) NR (one author from Johnson & Johnson Pharmaceuticals) To evaluate the efficacy and tolerability of a flexible dosing regimen of galantamine prolonged-release capsule compared with galantamine IR and placebo in patients with mild to moderate AD Study design: RCT Setting: Multi-center (93 sites) Sample size: 971 placebo galantamine galantamine PRC N/A 16 or 24 mg/d 16 or 24 mg/d 6 months 6 months 6 months 324 327 320 Clinical diagno
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
